-

Jerome Canady Research Institute for Advanced Biological and Technological Sciences Discovers Regulatory Gene BCL2A1 for Treatment of Triple-Negative Breast Cancer

TAKOMA PARK, Md.--(BUSINESS WIRE)--The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), announced today that their recent article, BCL2A1 REGULATES CANADY HELIOS COLD PLASMA-INDUCED CELL DEATH IN TRIPLE-NEGATIVE BREAST CANCER (TNBC), has been published in Scientific Reports, a Nature Portfolio journal. This novel discovery marks a significant advancement in cold plasma technology for cancer treatment.

JCRI-ABTS’s scientists demonstrated that a combination of Canady Helios™ Cold Plasma (CHCP) and anti-BCL2A1 treatment may be beneficial and a novel therapeutic option for triple-negative breast cancer and other solid tumor cancers.

BCL2A1 expression plays an important role in cell survival after CHCP treatment in breast cancer cells and is potentially regulated by TNF-alpha. Silencing BCL2A1 by siRNA treatment or by downregulating its expression by CPI203 treatment in combination with CHCP significantly increases the potency of the CHCP treatment.

Breast cancer is the leading cause of cancer death among women. Triple-negative breast cancer (TNBC) has a very poor prognosis and frequent relapses occur early compared with other cancer subtypes. CHCP is proving to be a promising therapy for a variety of prognostically poor breast cancer types and BCL2A1 could be a potential companion diagnostic biomarker.

According to Jerome Canady, MD, Chief Science Officer, “We investigated the expression profile of 48 apoptotic and 35 oxidative gene markers after CHCP Treatment during this study, and we are pleased to report Canady Helios Cold Plasma induced cell death in the TNBC cell lines”.

Dr. Taisen Zhuang, CTO of USMI revealed, “These outstanding results, discovered by our scientists, provide the solid theoretical foundation and will boost the commercialization process of Cold Plasma Oncotherapeutics™. Patients with TNBC will benefit from our cold plasma technology in the near future”.

JCRI-ABTS and sister company USMI have recently successfully completed a Phase 1 Clinical Trial using Canady Helios™ Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (FDA IDE #G190195).

About JCRI-ABTS

JCRI-ABTS is a state-of-the-art BSL 2 translational molecular research laboratory focusing on Plasma Oncotherapeutics (a new cancer treatment modality) using Canady Helios™ Cold Plasma to investigate the potential of Cold Atmospheric Plasma to selectively treat cancer

About US Medical Innovations

US Medical Innovations, LLC (USMI) is a private U.S. biomedical device company and wholly-owned subsidiary of US Patent Innovations, LLC. USMI’s focus is developing advanced innovative affordable plasma and robotic electrosurgical devices and striving to develop innovative devices in the field of plasma technology for the eradication of cancer.

Contacts

US Medical Innovations, LLC
Kenniah Chestnut, Esq. VP Corporate Affairs
301-270-0147
KChestnut@usmedinnov.com
www.usmedinnovations.com

US Medical Innovations, LLC


Release Summary
Jerome Canady Research Institute announces article: "BCL2A1 REGULATES CANADY HELIOS COLD PLASMA-INDUCED CELL DEATH IN TRIPLE-NEGATIVE BREAST CANCER."
Release Versions

Contacts

US Medical Innovations, LLC
Kenniah Chestnut, Esq. VP Corporate Affairs
301-270-0147
KChestnut@usmedinnov.com
www.usmedinnovations.com

More News From US Medical Innovations, LLC

US Medical Innovations Secures FDA Clearance for Canady Helios Cold Plasma™ Ablation System

TAKOMA PARK, Md.--(BUSINESS WIRE)--US Medical Innovations, LLC (USMI) announced today it has received FDA 510k Clearance (K240297) for the Canady Helios Cold Plasma™ (CHCP) Ablation System for the ablation of soft tissue during surgery. The CHCP system consists of the Canady Helios Cold Plasma XL-1000 CP Smart Electrosurgical Generator, Canady Helios Cold Plasma Ablators, Foot Pedal and Trolley Cart. Plasma is the fourth state of matter formed by ionizing neutral gases (i.e. Argon or Helium) co...

USMI to Debut the Canady Robotic AI Surgical System at the First Global Surgical Oncology Summit Jerusalem, Israel January 2024

TAKOMA PARK, Md.--(BUSINESS WIRE)--The Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) and US Medical Innovations, LLC (USMI) are pleased to announce today a ground-breaking achievement in surgical and robotic technology. The Canady Robotic AI Surgical System is the world’s first AI robotic system that delivers cold atmospheric plasma (CAP) which is a three-dimensional non-contact bioelectric pulse electromagnetic field. CAP selectively targets an...

Groundbreaking Results Using Canady Helios™ Cold Plasma Treatment Published in MDPI Journal “Cancers”

TAKOMA PARK, Md.--(BUSINESS WIRE)--The Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI) and US Medical Innovations, LLC (USMI) announced today that the full results from its successful FDA Phase 1 Clinical Trial has just been published in the scientific journal “Cancers”, a MDPI Publication. Despite advancements in surgery, chemotherapy, immunotherapy, and targeted therapies, local regional recurrence (LRR) of malignant solid tumors following surgical r...
Back to Newsroom